Completed PHASE1 INTERVENTIONAL 2-arm NCT03830125

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT-877 in Healthy Subjects

A Phase 1, 2-Stage, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT-877 Following Single and Multiple Ascending Doses in Healthy Adult Subjects

Sponsor: Bridge Biotherapeutics, Inc.

Conditions Idiopathic Pulmonary Fibrosis

Interventions BBT-877, Multiple doses BBT-877, Single dose Placebo group

Updated 7 times since 2019 Last updated: Jan 15, 2020 Started: Feb 13, 2019 Primary completion: Nov 24, 2019 Completion: Nov 24, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Idiopathic Pulmonary Fibrosis, this trial is completed. The trial is conducted by Bridge Biotherapeutics, Inc. and has accumulated 7 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Feb 2020 — Jan 2021 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Nov 2019 — Feb 2020 [monthly]

Recruiting PHASE1

▶ Show 2 earlier versions

Apr 2019 — Nov 2019 [monthly]

Recruiting PHASE1
Mar 2019 — Apr 2019 [monthly]

Recruiting PHASE1

First recorded

Feb 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bridge Biotherapeutics, Inc.
KCRN Research, LLC

Data source: Bridge Biotherapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lincoln, United States